Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on August 17, 2026. The report discloses a corporate governance update regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or operational metrics.
Material Changes
The material change disclosed is the appointment of Carol L. Brosgart, MD, to the Company's Board of Directors, announced via a press release on August 17, 2026.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The disclosure is limited to the board appointment under Regulation FD.
Key Facts for Investor Verification
- Verify the background and qualifications of the newly appointed director, Carol L. Brosgart, MD.
- Review the full text of the press release (Exhibit 99.1) for any additional context regarding the appointment.
- Confirm that no other material events were omitted from this specific 8-K filing.